The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis
Resection is still the only potentially curative treatment for patients with intrahepatic cholangiocarcinoma (ICC), but the prognosis remains far from satisfactory. However, the benefit of adjuvant therapy (AT) remains controversial, although it has been conducted prevalently. Hence, a meta-analysis...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-02, Vol.15 (2), p.e0229292-e0229292 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0229292 |
|---|---|
| container_issue | 2 |
| container_start_page | e0229292 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Ke, Qiao Lin, Nanping Deng, Manjun Wang, Lei Zeng, Yongyi Liu, Jingfeng |
| description | Resection is still the only potentially curative treatment for patients with intrahepatic cholangiocarcinoma (ICC), but the prognosis remains far from satisfactory. However, the benefit of adjuvant therapy (AT) remains controversial, although it has been conducted prevalently. Hence, a meta-analysis was warranted to evaluate the effect of AT for patients with ICC after resection.
PubMed, MedLine, Embase, the Cochrane Library, Web of Science were used to identify potentially eligible studies from Jan.1st 1990 to Aug. 31st 2019, investigating the effect of AT for patients with ICC after resection. Primary endpoint was overall survival (OS), and secondary endpoints was recurrence-free survival (RFS). Hazard ratio (HR) with 95% confidence interval (CI) was used to determine the effect size.
22 studies with 10181 patients were enrolled in this meta-analysis, including 832 patients in the chemotherapy group, 309 patients in the transarterial chemoembolization (TACE) group, 1192 patients in the radiotherapy group, 235 patients in the chemoradiotherapy group, and 6424 patients in the non-AT group. The pooled HR for the OS rate and RFS rate in the AT group were 0.63 (95%CI 0.52~0.74), 0.74 (95%CI 0.58~0.90), compared with the non-AT group. Subgroup analysis showed that the pooled HR for the OS rate in the AT group compared with non-AT group were as follows: chemotherapy group was 0.57 (95%CI = 0.44~0.70), TACE group was 0.56 (95%CI = 0.31~0.82), radiotherapy group was 0.71 (95%CI = 0.39~1.03), chemoradiotherapy group was 0.73 (95%CI = 0.57~0.89), positive resection margin group was 0.60 (95%CI = 0.51~0.69), and lymph node metastasis (LNM) group was 0.67 (95%CI = 0.57~0.76).
With the current data, we concluded that AT such as chemotherapy, TACE and chemoradiotherapy could benefit patients with ICC after resection, especially those with positive resection margin and LNM, but the conclusion needed to be furtherly confirmed. |
| doi_str_mv | 10.1371/journal.pone.0229292 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2360073360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A614629665</galeid><doaj_id>oai_doaj_org_article_8b50e157969745f5abbe11cc043353f7</doaj_id><sourcerecordid>A614629665</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-db5227779a054c28bc0479096e291ffbf82266477fafa113634a5a9d00b13f4a3</originalsourceid><addsrcrecordid>eNqNk11rFDEUhgdRbK3-A9GAIHqxaz5mMjteCKX4USgUtHobzmROdrLMTLZJpnX_hT_ZzHZbutILCUzCmed9k3OSk2UvGZ0zUbIPKzf6Abr52g04p5xXaTzKDlkl-ExyKh7fWx9kz0JYUVqIhZRPswPB6SLnjB5mfy5aJGgM6kicIdCsxisYIoktelhviHGerCFaHGIg1za2xA7RQ4tTUBPdug6GpXUavLaD64GAiehJGP3SauiIx5C8rRs-kmMSNiFiv1V6vLJ4TWBoSI8RZpBy2QQbnmdPDHQBX-zmo-znl88XJ99mZ-dfT0-Oz2ZaVjzOmrrgvCzLCmiRa76oNc3LilYSecWMqc2CcynzsjRggDEhRQ4FVA2lNRMmB3GUvb7xXXcuqF0xg-JCUlqK9E3E6Q3ROFiptbc9-I1yYNU24PxSgU-pdKgWdUGRFWUlqzIvTAF1jYzpdCYhCmHK5PVpt9tY99honIrY7Znu_xlsq5buSpVU5It8Mni3M_DucsQQVW-Dxi5VH924PTenVVVIntA3_6APZ7ejlpASsINxaV89mapjyXLJKymLRM0foNJosLc6vTxjU3xP8H5PkJiIv-MSxhDU6Y_v_8-e_9pn395jW4QutsF14_Sywj6Y34DauxA8mrsiM6qmxrmthpoaR-0aJ8le3b-gO9Ftp4i_mrcU2Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2360073360</pqid></control><display><type>article</type><title>The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ke, Qiao ; Lin, Nanping ; Deng, Manjun ; Wang, Lei ; Zeng, Yongyi ; Liu, Jingfeng</creator><contributor>Alpini, Gianfranco D.</contributor><creatorcontrib>Ke, Qiao ; Lin, Nanping ; Deng, Manjun ; Wang, Lei ; Zeng, Yongyi ; Liu, Jingfeng ; Alpini, Gianfranco D.</creatorcontrib><description>Resection is still the only potentially curative treatment for patients with intrahepatic cholangiocarcinoma (ICC), but the prognosis remains far from satisfactory. However, the benefit of adjuvant therapy (AT) remains controversial, although it has been conducted prevalently. Hence, a meta-analysis was warranted to evaluate the effect of AT for patients with ICC after resection.
PubMed, MedLine, Embase, the Cochrane Library, Web of Science were used to identify potentially eligible studies from Jan.1st 1990 to Aug. 31st 2019, investigating the effect of AT for patients with ICC after resection. Primary endpoint was overall survival (OS), and secondary endpoints was recurrence-free survival (RFS). Hazard ratio (HR) with 95% confidence interval (CI) was used to determine the effect size.
22 studies with 10181 patients were enrolled in this meta-analysis, including 832 patients in the chemotherapy group, 309 patients in the transarterial chemoembolization (TACE) group, 1192 patients in the radiotherapy group, 235 patients in the chemoradiotherapy group, and 6424 patients in the non-AT group. The pooled HR for the OS rate and RFS rate in the AT group were 0.63 (95%CI 0.52~0.74), 0.74 (95%CI 0.58~0.90), compared with the non-AT group. Subgroup analysis showed that the pooled HR for the OS rate in the AT group compared with non-AT group were as follows: chemotherapy group was 0.57 (95%CI = 0.44~0.70), TACE group was 0.56 (95%CI = 0.31~0.82), radiotherapy group was 0.71 (95%CI = 0.39~1.03), chemoradiotherapy group was 0.73 (95%CI = 0.57~0.89), positive resection margin group was 0.60 (95%CI = 0.51~0.69), and lymph node metastasis (LNM) group was 0.67 (95%CI = 0.57~0.76).
With the current data, we concluded that AT such as chemotherapy, TACE and chemoradiotherapy could benefit patients with ICC after resection, especially those with positive resection margin and LNM, but the conclusion needed to be furtherly confirmed.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0229292</identifier><identifier>PMID: 32084210</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adjuvant therapy ; Analysis ; Bile Duct Neoplasms - drug therapy ; Bile Duct Neoplasms - surgery ; Biliary tract cancer ; Cancer ; Cancer metastasis ; Care and treatment ; Chemoembolization ; Chemoradiotherapy ; Chemotherapy ; Chemotherapy, Adjuvant ; Cholangiocarcinoma ; Cholangiocarcinoma - drug therapy ; Cholangiocarcinoma - surgery ; Confidence intervals ; Hospitals ; Humans ; Liver cancer ; Lymph nodes ; Lymphatic system ; Medical prognosis ; Medical research ; Medicine and Health Sciences ; Meta-analysis ; Metastases ; People and Places ; Physical Sciences ; Prognosis ; Quality ; Radiation therapy ; Radiotherapy ; Research and Analysis Methods ; Studies ; Subgroups ; Surgery ; Survival ; Survival Analysis ; Systematic review ; Treatment Outcome</subject><ispartof>PloS one, 2020-02, Vol.15 (2), p.e0229292-e0229292</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Ke et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Ke et al 2020 Ke et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-db5227779a054c28bc0479096e291ffbf82266477fafa113634a5a9d00b13f4a3</citedby><cites>FETCH-LOGICAL-c692t-db5227779a054c28bc0479096e291ffbf82266477fafa113634a5a9d00b13f4a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034847/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034847/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32084210$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Alpini, Gianfranco D.</contributor><creatorcontrib>Ke, Qiao</creatorcontrib><creatorcontrib>Lin, Nanping</creatorcontrib><creatorcontrib>Deng, Manjun</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Zeng, Yongyi</creatorcontrib><creatorcontrib>Liu, Jingfeng</creatorcontrib><title>The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Resection is still the only potentially curative treatment for patients with intrahepatic cholangiocarcinoma (ICC), but the prognosis remains far from satisfactory. However, the benefit of adjuvant therapy (AT) remains controversial, although it has been conducted prevalently. Hence, a meta-analysis was warranted to evaluate the effect of AT for patients with ICC after resection.
PubMed, MedLine, Embase, the Cochrane Library, Web of Science were used to identify potentially eligible studies from Jan.1st 1990 to Aug. 31st 2019, investigating the effect of AT for patients with ICC after resection. Primary endpoint was overall survival (OS), and secondary endpoints was recurrence-free survival (RFS). Hazard ratio (HR) with 95% confidence interval (CI) was used to determine the effect size.
22 studies with 10181 patients were enrolled in this meta-analysis, including 832 patients in the chemotherapy group, 309 patients in the transarterial chemoembolization (TACE) group, 1192 patients in the radiotherapy group, 235 patients in the chemoradiotherapy group, and 6424 patients in the non-AT group. The pooled HR for the OS rate and RFS rate in the AT group were 0.63 (95%CI 0.52~0.74), 0.74 (95%CI 0.58~0.90), compared with the non-AT group. Subgroup analysis showed that the pooled HR for the OS rate in the AT group compared with non-AT group were as follows: chemotherapy group was 0.57 (95%CI = 0.44~0.70), TACE group was 0.56 (95%CI = 0.31~0.82), radiotherapy group was 0.71 (95%CI = 0.39~1.03), chemoradiotherapy group was 0.73 (95%CI = 0.57~0.89), positive resection margin group was 0.60 (95%CI = 0.51~0.69), and lymph node metastasis (LNM) group was 0.67 (95%CI = 0.57~0.76).
With the current data, we concluded that AT such as chemotherapy, TACE and chemoradiotherapy could benefit patients with ICC after resection, especially those with positive resection margin and LNM, but the conclusion needed to be furtherly confirmed.</description><subject>Adjuvant therapy</subject><subject>Analysis</subject><subject>Bile Duct Neoplasms - drug therapy</subject><subject>Bile Duct Neoplasms - surgery</subject><subject>Biliary tract cancer</subject><subject>Cancer</subject><subject>Cancer metastasis</subject><subject>Care and treatment</subject><subject>Chemoembolization</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cholangiocarcinoma</subject><subject>Cholangiocarcinoma - drug therapy</subject><subject>Cholangiocarcinoma - surgery</subject><subject>Confidence intervals</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Lymph nodes</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Meta-analysis</subject><subject>Metastases</subject><subject>People and Places</subject><subject>Physical Sciences</subject><subject>Prognosis</subject><subject>Quality</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Research and Analysis Methods</subject><subject>Studies</subject><subject>Subgroups</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Systematic review</subject><subject>Treatment Outcome</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11rFDEUhgdRbK3-A9GAIHqxaz5mMjteCKX4USgUtHobzmROdrLMTLZJpnX_hT_ZzHZbutILCUzCmed9k3OSk2UvGZ0zUbIPKzf6Abr52g04p5xXaTzKDlkl-ExyKh7fWx9kz0JYUVqIhZRPswPB6SLnjB5mfy5aJGgM6kicIdCsxisYIoktelhviHGerCFaHGIg1za2xA7RQ4tTUBPdug6GpXUavLaD64GAiehJGP3SauiIx5C8rRs-kmMSNiFiv1V6vLJ4TWBoSI8RZpBy2QQbnmdPDHQBX-zmo-znl88XJ99mZ-dfT0-Oz2ZaVjzOmrrgvCzLCmiRa76oNc3LilYSecWMqc2CcynzsjRggDEhRQ4FVA2lNRMmB3GUvb7xXXcuqF0xg-JCUlqK9E3E6Q3ROFiptbc9-I1yYNU24PxSgU-pdKgWdUGRFWUlqzIvTAF1jYzpdCYhCmHK5PVpt9tY99honIrY7Znu_xlsq5buSpVU5It8Mni3M_DucsQQVW-Dxi5VH924PTenVVVIntA3_6APZ7ejlpASsINxaV89mapjyXLJKymLRM0foNJosLc6vTxjU3xP8H5PkJiIv-MSxhDU6Y_v_8-e_9pn395jW4QutsF14_Sywj6Y34DauxA8mrsiM6qmxrmthpoaR-0aJ8le3b-gO9Ftp4i_mrcU2Q</recordid><startdate>20200221</startdate><enddate>20200221</enddate><creator>Ke, Qiao</creator><creator>Lin, Nanping</creator><creator>Deng, Manjun</creator><creator>Wang, Lei</creator><creator>Zeng, Yongyi</creator><creator>Liu, Jingfeng</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200221</creationdate><title>The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis</title><author>Ke, Qiao ; Lin, Nanping ; Deng, Manjun ; Wang, Lei ; Zeng, Yongyi ; Liu, Jingfeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-db5227779a054c28bc0479096e291ffbf82266477fafa113634a5a9d00b13f4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adjuvant therapy</topic><topic>Analysis</topic><topic>Bile Duct Neoplasms - drug therapy</topic><topic>Bile Duct Neoplasms - surgery</topic><topic>Biliary tract cancer</topic><topic>Cancer</topic><topic>Cancer metastasis</topic><topic>Care and treatment</topic><topic>Chemoembolization</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cholangiocarcinoma</topic><topic>Cholangiocarcinoma - drug therapy</topic><topic>Cholangiocarcinoma - surgery</topic><topic>Confidence intervals</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Lymph nodes</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Meta-analysis</topic><topic>Metastases</topic><topic>People and Places</topic><topic>Physical Sciences</topic><topic>Prognosis</topic><topic>Quality</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Research and Analysis Methods</topic><topic>Studies</topic><topic>Subgroups</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Systematic review</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ke, Qiao</creatorcontrib><creatorcontrib>Lin, Nanping</creatorcontrib><creatorcontrib>Deng, Manjun</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Zeng, Yongyi</creatorcontrib><creatorcontrib>Liu, Jingfeng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ke, Qiao</au><au>Lin, Nanping</au><au>Deng, Manjun</au><au>Wang, Lei</au><au>Zeng, Yongyi</au><au>Liu, Jingfeng</au><au>Alpini, Gianfranco D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-02-21</date><risdate>2020</risdate><volume>15</volume><issue>2</issue><spage>e0229292</spage><epage>e0229292</epage><pages>e0229292-e0229292</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Resection is still the only potentially curative treatment for patients with intrahepatic cholangiocarcinoma (ICC), but the prognosis remains far from satisfactory. However, the benefit of adjuvant therapy (AT) remains controversial, although it has been conducted prevalently. Hence, a meta-analysis was warranted to evaluate the effect of AT for patients with ICC after resection.
PubMed, MedLine, Embase, the Cochrane Library, Web of Science were used to identify potentially eligible studies from Jan.1st 1990 to Aug. 31st 2019, investigating the effect of AT for patients with ICC after resection. Primary endpoint was overall survival (OS), and secondary endpoints was recurrence-free survival (RFS). Hazard ratio (HR) with 95% confidence interval (CI) was used to determine the effect size.
22 studies with 10181 patients were enrolled in this meta-analysis, including 832 patients in the chemotherapy group, 309 patients in the transarterial chemoembolization (TACE) group, 1192 patients in the radiotherapy group, 235 patients in the chemoradiotherapy group, and 6424 patients in the non-AT group. The pooled HR for the OS rate and RFS rate in the AT group were 0.63 (95%CI 0.52~0.74), 0.74 (95%CI 0.58~0.90), compared with the non-AT group. Subgroup analysis showed that the pooled HR for the OS rate in the AT group compared with non-AT group were as follows: chemotherapy group was 0.57 (95%CI = 0.44~0.70), TACE group was 0.56 (95%CI = 0.31~0.82), radiotherapy group was 0.71 (95%CI = 0.39~1.03), chemoradiotherapy group was 0.73 (95%CI = 0.57~0.89), positive resection margin group was 0.60 (95%CI = 0.51~0.69), and lymph node metastasis (LNM) group was 0.67 (95%CI = 0.57~0.76).
With the current data, we concluded that AT such as chemotherapy, TACE and chemoradiotherapy could benefit patients with ICC after resection, especially those with positive resection margin and LNM, but the conclusion needed to be furtherly confirmed.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>32084210</pmid><doi>10.1371/journal.pone.0229292</doi><tpages>e0229292</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-02, Vol.15 (2), p.e0229292-e0229292 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2360073360 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adjuvant therapy Analysis Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - surgery Biliary tract cancer Cancer Cancer metastasis Care and treatment Chemoembolization Chemoradiotherapy Chemotherapy Chemotherapy, Adjuvant Cholangiocarcinoma Cholangiocarcinoma - drug therapy Cholangiocarcinoma - surgery Confidence intervals Hospitals Humans Liver cancer Lymph nodes Lymphatic system Medical prognosis Medical research Medicine and Health Sciences Meta-analysis Metastases People and Places Physical Sciences Prognosis Quality Radiation therapy Radiotherapy Research and Analysis Methods Studies Subgroups Surgery Survival Survival Analysis Systematic review Treatment Outcome |
| title | The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T19%3A06%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20adjuvant%20therapy%20for%20patients%20with%20intrahepatic%20cholangiocarcinoma%20after%20surgical%20resection:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=PloS%20one&rft.au=Ke,%20Qiao&rft.date=2020-02-21&rft.volume=15&rft.issue=2&rft.spage=e0229292&rft.epage=e0229292&rft.pages=e0229292-e0229292&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0229292&rft_dat=%3Cgale_plos_%3EA614629665%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2360073360&rft_id=info:pmid/32084210&rft_galeid=A614629665&rft_doaj_id=oai_doaj_org_article_8b50e157969745f5abbe11cc043353f7&rfr_iscdi=true |